Curis is a biotechnology company seeking to develop and commercialize innovative drug candidates for the treatment of human cancers. Our most advanced drug candidate is CUDC-907, an oral, small molecule inhibitor of histone deacetylase (HDAC), and phosphatidylinositol-3-kinase (PI3K) enzymes. Curis is also in a collaboration with Aurigene in the areas of immune-oncology and precision oncology. As part of this collaboration, we expect to exercise options to exclusively license small molecule antagonists. The 1st program is focused on the development of orally-available small molecule antagonist of PD-1 and VISTA in immuno-oncology, CA-170, currently in Phase I trials.

Our most advanced program, a Hedgehog pathway inhibitor program developed in collaboration with Genentech (Roche), led to the commercialization of Erivedge® (vismodegib), the first FDA-approved medicine for advanced basal cell carcinoma. Genentech/Roche are responsible for the worldwide commercialization of Erivedge.